Mechanism of and therapeutic strategy for atrial fibrillation associated with diabetes mellitus

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Lin, Yubi ^a   Li, Hairui ^a   Lan, Xianwu ^a   Chen, Xianghui ^a   Zhang, Aidong ^a   Li, Zicheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS GLYCOSIDE; GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; ANTIDIABETIC AGENT;

ANTICOAGULANT THERAPY; CARDIOVASCULAR RISK; CATHETER ABLATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTERNATIONAL NORMALIZED RATIO; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SINUS RHYTHM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ATRIAL FIBRILLATION; CATHETER ABLATION; COMBINED MODALITY THERAPY; DIABETES COMPLICATIONS; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84876514360     PISSN: 1537744X     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/209428     Document Type: Review

References (51)

1. Watson T., Shantsila E., Lip G. Y., Mechanisms of thrombogenesis in atrial fibrillation: virchow's triad revisited. The Lancet 2009 373 9658 155 166 2-s2.0-58149204184 10.1016/S0140-6736(09)60040-4
2. Steger C., Pratter A., Martinek-Bregel M., Avanzini M., Valentin A., Slany J., Stöllberger C., Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. European Heart Journal 2004 25 19 1734 1740 2-s2.0-4644340409 10.1016/j.ehj.2004.06.030 (Pubitemid 39286639)
3. Movahed M. R., Hashemzadeh M., Mazen Jamal M., Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. International Journal of Cardiology 2005 105 3 315 318 2-s2.0-27744587081 10.1016/j.ijcard.2005.02.050 (Pubitemid 41605083)
4. Aksnes T. A., Schmieder R. E., Kjeldsen S. E., Ghani S., Hua T. A., Julius S., Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). American Journal of Cardiology 2008 101 5 634 638 2-s2.0-41949131420 10.1016/j.amjcard.2007.10.025 (Pubitemid 351625088)
5. Nichols G. A., Reinier K., Chugh S. S., Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009 32 10 1851 1856 2-s2.0-70349675746 10.2337/dc09-0939
6. Huxley R. R., Filion K. B., Konety S., Alonso A., Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. American Journal of Cardiology 2011 108 1 56 62 2-s2.0-79958814579 10.1016/j.amjcard.2011.03.004
7. Johansen O. E., Brustad E., Enger S., Tveit A., Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects. Cardiovascular Diabetology 2008 7, article 28 2-s2.0-53949123542 10.1186/1475-2840-7-28
8. Östgren C. J., Merlo J., Råstam L., Lindblad U., Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes, Obesity and Metabolism 2004 6 5 367 374 2-s2.0-4444364450 10.1111/j.1462-8902.2004.00358.x (Pubitemid 39172859)
9. Chamberlain A. M., Agarwal S. K., Ambrose M., Folsom A. R., Soliman E. Z., Alonso A., Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. American Heart Journal 2010 159 5 850 856 2-s2.0-77951540399 10.1016/j.ahj.2010.02.005
10. Dublin S., Glazer N. L., Smith N. L., Psaty B. M., Lumley T., Wiggins K. L., Page R. L., Heckbert S. R., Diabetes mellitus, glycemic control, and risk of atrial fibrillation. Journal of General Internal Medicine 2010 25 8 853 858 2-s2.0-77954424113 10.1007/s11606-010-1340-y
11. Huxley R. R., Alonso A., Lopez F. L., Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 2012 98 2 133 138
12. Sugishita K., Shiono E., Sugiyama T., Ashida T., Diabetes influences the cardiac symptoms related to atrial fibrillation. Circulation Journal 2003 67 10 835 838 2-s2.0-0141926562 10.1253/circj.67.835 (Pubitemid 37229220)
13. Du X., Ninomiya T., De Galan B., Abadir E., Chalmers J., Pillai A., Woodward M., Cooper M., Harrap S., Hamet P., Poulter N., Lip G. Y. H., Patel A., Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. European Heart Journal 2009 30 9 1128 1135 2-s2.0-65949110355 10.1093/eurheartj/ehp055
14. Soran H., Younis N., Currie P., Silas J., Jones I. R., Gill G., Influence of diabetes on the maintenance of sinus rhythm after a successful direct current cardioversion in patients with atrial fibrillation. Quarterly Journal of Medicine 2008 101 3 181 187 2-s2.0-39849109823 10.1093/qjmed/hcm123 (Pubitemid 351315007)
15. Guazzi M., Belletti S., Lenatti L., Bianco E., Guazzi M. D., Effects of cardioversion of atrial fibrillation on endothelial function in hypertension or diabetes. European Journal of Clinical Investigation 2007 37 1 26 34 2-s2.0-33845584642 10.1111/j.1365-2362.2007.01744.x (Pubitemid 44934769)
16. Guazzi M., Belletti S., Bianco E., Lenatti L., Guazzi M. D., Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: different results with cardioversion. American Journal of Physiology 2006 291 2 H921 H928 2-s2.0-33746851508 10.1152/ajpheart.00986.2005 (Pubitemid 44175102)
17. Lip G. Y. H., Varughese G. I., Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. International Journal of Cardiology 2005 105 3 319 321 2-s2.0-27744526856 10.1016/j.ijcard. 2005.03.003 (Pubitemid 41613592)
18. Pop-Busui R., Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010 33 2 434 441 2-s2.0-75149144006 10.2337/dc09-1294
19. The Diabetes Control and Complications Trial Research Group, The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998 41 4 416 423
20. Kennedy W. R., Navarro X., Sutherland D. E. R., Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology 1995 45 4 773 780 2-s2.0-0028951205
21. Ziegler D., Dannehl K., Muhlen H., Spuler M., Gries F. A., Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabetic Medicine 1992 9 9 806 814 2-s2.0-0026475975
22. Voulgari C., Psallas M., Kokkinos A., Argiana V., Katsilambros N., Tentolouris N., The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. Journal of Diabetes and its Complications 2011 25 3 159 167 2-s2.0-79955053061 10.1016/j.jdiacomp.2010.06.001
23. Urbančič-Rovan V., Meglič B., Stefanovska A., Bernjak A., Ažman-Juvan K., Kocijančič A., Incipient cardiovascular autonomic imbalance revealed by wavelet analysis of heart rate variability in type 2 diabetic patients. Diabetic Medicine 2007 24 1 18 26 2-s2.0-33846185514 10.1111/j.1464-5491.2007.02019.x (Pubitemid 46103067)
24. Otake H., Suzuki H., Honda T., Maruyama Y., Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. International Heart Journal 2009 50 5 627 641 2-s2.0-74849106152 10.1536/ihj.50.627
25. Boudina S., Abel E. D., Diabetic cardiomyopathy, causes and effects. Reviews in Endocrine and Metabolic Disorders 2010 11 1 31 39 2-s2.0-77953440109 10.1007/s11154-010-9131-7
26. Kato T., Yamashita T., Sekiguchi A., Sagara K., Takamura M., Takata S., Kaneko S., Aizawa T., Fu L. T., What are arrhythmogenic substrates in diabetic rat atria? Journal of Cardiovascular Electrophysiology 2006 17 8 890 894 2-s2.0-33746047722 10.1111/j.1540-8167.2006.00528.x (Pubitemid 44079750)
27. Chao T. F., Suenari K., Chang S. L., Lin Y. J., Lo L. W., Hu Y. F., Tuan T. C., Tai C. T., Tsao H. M., Li C. H., Ueng K. C., Wu T. J., Chen S. A., Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. American Journal of Cardiology 2010 106 11 1615 1620 2-s2.0-78649332334 10.1016/j.amjcard.2010.07.038
28. Karabag T., Aydin M., Dogan S. M., Ali Cetiner M., Sayin M. R., Gudul N. E., Kucuk E., Prolonged P wave dispersion in pre-diabetic patients. Kardiologia Polska 2011 69 6 566 571 2-s2.0-79959302976
29. Anderson E. J., Kypson A. P., Rodriguez E., Anderson C. A., Lehr E. J., Neufer P. D., Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. Journal of the American College of Cardiology 2009 54 20 1891 1898 2-s2.0-70350445742 10.1016/j.jacc.2009.07.031
30. Mitašíková M., Lin H., Soukup T., Imanaga I., Tribulová N., Diabetes and thyroid hormones affect connexin-43 and PKC- ε expression in rat heart atria. Physiological Research 2009 58 2 211 217 2-s2.0-66349103649
31. Kato T., Yamashita T., Sekiguchi A., Tsuneda T., Sagara K., Takamura M., Kaneko S., Aizawa T., Fu L. T., AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. Journal of Cardiovascular Electrophysiology 2008 19 4 415 420 2-s2.0-41449108092 10.1111/j.1540-8167.2007.01037.x (Pubitemid 351457548)
32. Rigalleau V., Baillet L., Hocini M., Gin H., Atrial fibrillation can cause major hyperglycemia. Diabetes and Metabolism 2002 28 3 239 240 2-s2.0-0035986344 (Pubitemid 34746959)
33. Camm A. J., Kirchhof P., Lip G. Y., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010 12 10 1360 1420
34. Ehrlich J. R., Hohnloser S. H., Mattel S., Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. European Heart Journal 2006 27 5 512 518 2-s2.0-33645236163 10.1093/eurheartj/ehi668
35. Caballero R., Delpón E., Valenzuela C., Longobardo M., Tamargo J., Losartan and its metabolite E3174 modify cardiac delayed rectifier K+ currents. Circulation 2000 101 10 1199 1205 2-s2.0-0034646388 (Pubitemid 30146624)
36. De Mello W. C., Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension 1998 32 6 976 982 2-s2.0-0032407402 (Pubitemid 29001423)
37. Fareh S., Bénardeau A., Thibault B., Nattel S., The T-type Ca2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999 100 21 2191 2197 2-s2.0-0345440145
38. Unger T., Neurohormonal modulation in cardiovascular disease. American Heart Journal 2000 139 1 S2 S8 2-s2.0-0033988042 (Pubitemid 30041750)
39. Fogari R., Zoppi A., Mugellini A., Corradi L., Lazzari P., Preti P., Derosa G., Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. Journal of Cardiovascular Pharmacology 2008 51 3 217 222 2-s2.0-41349084427 10.1097/FJC.0b013e318160b42a (Pubitemid 351450598)
40. Liu T., Korantzopoulos P., Li G., Li J., The potential role of thiazolidinediones in atrial fibrillation. International Journal of Cardiology 2008 128 1 129 130 2-s2.0-46149126162 10.1016/j.ijcard.2007.05.051 (Pubitemid 351905768)
41. Chao T. F., Leu H. B., Huang C. C., Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. International Journal of Cardiology 2012 156 2 199 202
42. Anglade M. W., Kluger J., White C. M., Aberle J., Coleman C. I., Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study. Current Medical Research and Opinion 2007 23 11 2849 2855 2-s2.0-36348941039 10.1185/030079907X242494 (Pubitemid 350146423)
43. Shimano M., Tsuji Y., Inden Y., Kitamura K., Uchikawa T., Harata S., Nattel S., Murohara T., Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008 5 3 451 459 2-s2.0-39649093243 10.1016/j.hrthm.2007.12.010
44. Kume O., Takahashi N., Wakisaka O., Nagano-Torigoe Y., Teshima Y., Nakagawa M., Yufu K., Hara M., Saikawa T., Yoshimatsu H., Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011 8 2 278 285 2-s2.0-79251565539 10.1016/j.hrthm.2010.10.029
45. Vaiopoulos A. G., Marinou K., Christodoulides C., The role of adiponectin in human vascular physiology. International Journal of Cardiology 2012 155 2 188 193
46. Li G., Liu T., The therapeutic strategies of enhancing adiponectin and lowering leptin may be benefit to controlling atrial fibrillation. Medical Hypotheses 2009 73 1 122 2-s2.0-64749104186 10.1016/j.mehy.2009.02.005
47. Xu D., Murakoshi N., Igarashi M., PPAR-gamma activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. Journal of Cardiovascular Electrophysiology 2012 23 2 209 217
48. Liu T., Li G., Thiazolidinediones as novel upstream therapy for atrial fibrillation in diabetic patients: a review of current evidence. International Journal of Cardiology 2012 156 2 215 216
49. Tang R. B., Dong J. Z., Liu X. P., Fang D. P., Long D. Y., Liu X. H., Yu R. H., Hu F. L., Lu C. S., Hao P., Kalifa J., Ma C. S., Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus-single center experience. Journal of Interventional Cardiac Electrophysiology 2006 17 1 41 46 2-s2.0-33847139430 10.1007/s10840-006-9049-x (Pubitemid 46295282)
50. Forleo G. B., Mantica M., De Luca L., Leo R., Santini L., Panigada S., De Sanctis V., Pappalardo A., Laurenzi F., Avella A., Casella M., Russo A. D., Romeo F., Pelargonio G., Tondo C., Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. Journal of Cardiovascular Electrophysiology 2009 20 1 22 28 2-s2.0-58149229426 10.1111/j.1540-8167.2008.01275.x
51. Gu J., Liu X., Wang X., Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011 13 9 1256 1261